Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 5802674, 11 pages
http://dx.doi.org/10.1155/2016/5802674
Review Article

The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis

Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, China

Received 4 January 2016; Revised 20 February 2016; Accepted 17 March 2016

Academic Editor: Manuela Neuman

Copyright © 2016 Jiao Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. K. Sarin, A. Kumar, J. A. Almeida et al., “Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL),” in Hepatology International, vol. 3, article 269, 2009. View at Publisher · View at Google Scholar
  2. L. J. Sun, J. W. Yu, Y. H. Zhao, P. Kang, and S. C. Li, “Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure,” Journal of Gastroenterology and Hepatology, vol. 25, no. 3, pp. 583–590, 2010. View at Publisher · View at Google Scholar
  3. C. Vickers, J. Neuberger, J. Buckels, P. McMaster, and E. Elias, “Transplantation of the liver in adults and children with fulminant hepatic failure,” Journal of Hepatology, vol. 7, no. 2, pp. 143–150, 1988. View at Publisher · View at Google Scholar · View at Scopus
  4. X. Xu, X. Liu, Q. Ling et al., “Artificial Liver Support System Combined with Liver Transplantation in the Treatment of Patients with Acute-on-Chronic Liver Failure,” PLoS ONE, vol. 8, no. 3, p. e58738, 2013. View at Publisher · View at Google Scholar
  5. V. Stadlbauer, N. A. Davies, S. Sen, and R. Jalan, “Artificial liver support systems in the management of complications of cirrhosis,” Seminars in Liver Disease, vol. 28, no. 1, pp. 96–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Bahirwani, O. Shaked, M. Bewtra, K. Forde, and K. R. Reddy, “Acute-on-chronic liver failure before liver transplantation: impact on posttransplant outcomes,” Transplantation, vol. 92, no. 8, pp. 952–957, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. C. Chan, S. T. Fan, C. M. Lo et al., “Liver transplantation for acute-on-chronic liver failure,” Hepatology International, vol. 3, no. 4, pp. 571–581, 2009. View at Publisher · View at Google Scholar
  8. X. Ren, Z. Xu, Y. Liu et al., “Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis,” Journal of Viral Hepatitis, vol. 17, no. 12, pp. 887–895, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-Y. Zhang, Z. Zhang, F. Lin et al., “Interleukin-17-producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B,” Hepatology, vol. 51, no. 1, pp. 81–91, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. Q. L. Song, X. X. He, H. Yang et al., “Association of a TANK gene polymorphism with outcomes of hepatitis B virus infection in a Chinese Han population,” Viral Immunology, vol. 25, no. 1, pp. 73–78, 2012. View at Publisher · View at Google Scholar
  11. Y. Rong, H. Song, S. You et al., “Association of toll-like receptor 3 polymorphisms with chronic hepatitis b and hepatitis B-related acute-on-chronic liver failure,” Inflammation, vol. 36, no. 2, pp. 413–418, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Haché and J.-P. Villeneuve, “Lamivudine treatment in patients with chronic hepatitis B and cirrhosis,” Expert Opinion on Pharmacotherapy, vol. 7, no. 13, pp. 1835–1843, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. F. Liaw, J. J. Sung, W. C. Chow et al., “Cirrhosis Asian Lamivudine Multicentre Study Group: lamivudine for patients with chronic hepatitis B and advanced liver disease,” The New England Journal of Medicine, vol. 351, pp. 1521–1531, 2004. View at Google Scholar
  14. X. Zhang, L. Liu, M. Zhang et al., “The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis,” Annals of Hepatology, vol. 14, no. 2, pp. 150–160, 2015. View at Google Scholar · View at Scopus
  15. S. Yu, H. Jianqin, W. Wei et al., “The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis,” Annals of Hepatology, vol. 12, no. 3, pp. 364–372, 2013. View at Google Scholar
  16. F. Xie, L. Yan, J. Lu et al., “Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis,” PLoS ONE, vol. 8, no. 1, Article ID e54773, 2013. View at Publisher · View at Google Scholar
  17. T.-T. Chang, R. G. Gish, R. de Man et al., “A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B,” New England Journal of Medicine, vol. 354, no. 10, pp. 1001–1010, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. C.-L. Lai, D. Shouval, A. S. Lok et al., “Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B,” New England Journal of Medicine, vol. 354, no. 10, pp. 1011–1020, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Wen, J. Tuan, M. D. Hu, J. H. Zhang, M. Wu, and S. M. Yao, “A comparison of entecavir and lamivudine for subacute-on-chronic liver failure infected with HBV,” Journal of Tropical Medicine, vol. 10, pp. 183–185, 2010 (Chinese). View at Google Scholar
  20. M. F. Yuen, “Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure,” Hepatology International, vol. 9, no. 3, pp. 373–377, 2015. View at Publisher · View at Google Scholar
  21. Y. Zhang, X.-Y. Hu, S. Zhong et al., “Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure,” World Journal of Gastroenterology, vol. 20, no. 16, pp. 4745–4752, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. L. Cui, F. Yan, Y. B. Wang et al., “Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure,” Digestive Diseases and Sciences, vol. 55, no. 8, pp. 2373–2380, 2010. View at Publisher · View at Google Scholar
  23. D. Moher, L. Shamseer, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement,” Systematic Reviews, vol. 4, no. 1, 2015. View at Publisher · View at Google Scholar
  24. S. K. Sarin, C. K. Kedarisetty, Z. Abbas et al., “Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014,” Hepatology International, vol. 8, no. 4, pp. 453–471, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. J. H. Hu, H. F. Wang, W. P. He et al., “Lamivudine and entecavir significantly improved the prognosis of early-to-mid stage hepatitis B related acute on chronic liver failure,” Chinese Journal of Experimental and Clinical Virology, vol. 24, pp. 205–208, 2010 (Chinese). View at Google Scholar
  26. H. Gao, M. Lin, C. Pan et al., “Nucleoside analogues for acute-on-chronic liver failure associated with hepatitis B virus infection: a 24-month survival analysis,” Chinese Journal of Hepatology, vol. 23, no. 1, pp. 17–22, 2015 (Chinese). View at Publisher · View at Google Scholar · View at Scopus
  27. T. Chen, Y. He, X. Liu et al., “Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure,” Clinical and Experimental Medicine, vol. 12, no. 3, pp. 159–164, 2012. View at Publisher · View at Google Scholar
  28. J. Lai, Y. Yan, L. Mai, Y.-B. Zheng, W.-Q. Gan, and W.-M. Ke, “Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure,” Hepatobiliary and Pancreatic Diseases International, vol. 12, no. 2, pp. 154–159, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. W. H. Cai and C. F. Shi, “Efficacy comparison of entecaavir and lamivudine in patients with HBV-associated acute-on-chronic liver failure,” Guide of China Medicine, vol. 9, pp. 303–304, 2011 (Chinese). View at Google Scholar
  30. B. He, “Short-term efficacy comparison of lamivudine and entecavir in patients with HBV-associated acut-on-chronic liver failure,” Hebei Medical Journal, vol. 35, pp. 661–663, 2013 (Chinese). View at Google Scholar
  31. L. Yuan, “Comparison between entecavir and lamivudine for acute on chronic liver failure caused by HBV,” China & Foreign Medical Treatment, vol. 12, pp. 107–108, 2015 (Chinese). View at Google Scholar
  32. G. Ostapowicz, R. J. Fontana, F. V. Schioødt et al., “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States,” Annals of Internal Medicine, vol. 137, no. 12, pp. 947–954, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Rutherford, T. Davern, J. E. Hay et al., “Influence of high body mass index on outcome in acute liver failure,” Clinical Gastroenterology and Hepatology, vol. 4, no. 12, pp. 1544–1549, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. C. A. Philips and S. K. Sarin, “Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation,” World Journal of Gastroenterology, vol. 20, no. 43, pp. 16037–16052, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Zhao, T. Han, and Y. Gao, “Analysis on the predisposing cause and outcome of 289 cases of hepatitis B patients complicated with chronic or acute liver failure,” World Journal of Gastroenterology, vol. 17, pp. 3269–3272, 2009. View at Google Scholar
  36. C. M. Lange, J. Bojunga, W. P. Hofmann et al., “Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function,” Hepatology, vol. 50, no. 6, pp. 2001–2006, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. R.-N. Chien, C.-H. Lin, and Y.-F. Liaw, “The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B,” Journal of Hepatology, vol. 38, no. 3, pp. 322–327, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Tsubota, Y. Arase, Y. Suzuki et al., “Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B,” Journal of Gastroenterology and Hepatology, vol. 20, no. 3, pp. 426–432, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. E. B. Keeffe, D. Dieterich, S.-H. B. Han et al., “A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update,” Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1315–1341, 2008. View at Publisher · View at Google Scholar